Search results for "Highlights"
Manufacturer's trials find positive results for combo drug for type 2 diabetes
Tirzepatide, a not-yet-approved dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, was tested against placebo and semaglutide in recent studies.
https://diabetes.acponline.org/archives/2021/07/09/3.htm
9 Jul 2021
SGLT-2 inhibitors associated with reduced heart failure events versus metformin
A retrospective study of patients who took sodium-glucose cotransporter-2 (SGLT-2) inhibitors or metformin as first-line therapy for type 2 diabetes found similar risk for myocardial infarction and stroke with the two drug classes but a difference in hospitalizations for heart failure.
https://diabetes.acponline.org/archives/2022/06/10/2.htm
10 Jun 2022
Review finds blood pressure-lowering effects weaker in patients with type 2 diabetes
Absolute risk reductions did not differ substantially between people with and without type 2 diabetes because of the higher absolute cardiovascular risk among those with the condition, according to a new meta-analysis.
https://diabetes.acponline.org/archives/2022/08/12/1.htm
12 Aug 2022
Whole, plant-based diet most effective for type 2 diabetes remission, ACLM says
Diet as a primary intervention can achieve remission for many with type 2 diabetes and should focus on plant-based foods with minimal consumption of meat and other animal products, according to a statement from the American College of Lifestyle Medicine (ACLM).
https://diabetes.acponline.org/archives/2022/06/10/3.htm
10 Jun 2022
Spotlight on efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists
One recent study compared sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists to each other, a meta-analysis tried to quantify their benefits compared to placebo, and a third study looked at their effects relative to insulin.
https://diabetes.acponline.org/archives/2022/05/13/5.htm
13 May 2022
GLP-1 receptor agonists linked to increased risk of gallbladder, biliary diseases
A systematic review and meta-analysis of 76 randomized trials found that use of glucagon-like peptide-1 (GLP-1) receptor agonists was associated with increased risk of gallbladder or biliary diseases, especially when used at higher doses, for longer durations, and for weight loss.
https://diabetes.acponline.org/archives/2022/04/08/2.htm
8 Apr 2022
Glucose-lowering treatment after type 2 diabetes diagnosis differed by race/ethnicity
Among 77,199 patients in a U.S. health system with a new diagnosis of diabetes from 2005 to 2016, 47% started a diabetes medication within 12 months. Prevalence differed by race and ethnicity, although the difference was mitigated by variation in HbA1c levels.
https://diabetes.acponline.org/archives/2022/08/12/3.htm
12 Aug 2022
Statins compared for non-HDL cholesterol levels in patients with diabetes
Moderate- and high-intensity rosuvastatin and high-intensity simvastatin and atorvastatin were most effective at moderately reducing levels of non-high-density lipoprotein (HDL) cholesterol, a systematic review and meta-analysis found.
https://diabetes.acponline.org/archives/2022/04/08/1.htm
8 Apr 2022
Unrecognized risk factors for severe hypoglycemia outlined in insulin-treated type 2 diabetes
An industry-funded case-control study of data from a U.S. administrative claims database found that pregnancy, alcohol misuse, short or rapid-acting insulin, and smoking, among other conditions and medications, were independently associated with increased risk.
https://diabetes.acponline.org/archives/2022/04/08/3.htm
8 Apr 2022
SGLT-2 inhibitors reduce cardiac events, mortality compared to DPP-4 inhibitors
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors were associated with lower risk of cardiovascular events compared to dipeptidyl peptidase-4 (DPP-4) inhibitors but higher risk of genital infections and diabetic ketoacidosis, a retrospective study found.
https://diabetes.acponline.org/archives/2023/02/10/1.htm
10 Feb 2023